This project will facilitate tracking of a polymer nanomedicine in vivo using both the newly developed 19F MRI technology along with other imaging modalities e.g. PET. The novel imaging approach uses a therapeutic-carrying 19F MR imaging agent. The imaging agent is capable of releasing a therapeutic payload under acidic pH conditions, upon which the agent is switched β€˜ON’ and can then be imaged using 19F MRI. The lack of endogenous fluorine in the body means that the contrast agent will be visualised as a bright spot within the MRI resonator. In combination with PET radionuclide imaging, this material provides a useful tool for monitoring biodistribution, accumulation and release of therapeutics in tumour models.

Project members

Associate Professor Kris Thurecht

Group Leader - Principal Research Fellow
Centre for Advanced Imaging